News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phase III U.S. Pivotal Study Results on CSL Biotherapies' Afluria(R) Published in Vaccine



9/3/2008 9:22:12 AM

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Phase III pivotal study findings in the journal Vaccine showed that two formulations of CSL Biotherapies’ influenza virus vaccine Afluria® elicited an immune response (also known as immunogenicity) in healthy adults aged 18 - <65 years. The results, from a study performed at nine centers affiliated with the National Institutes of Health (NIH), met the U.S. Food and Drug Administration’s (FDA) requirements for influenza vaccine immunogenicity. These data formed the basis of CSL Biotherapies’ US biologics licensing application for Afluria that was approved through priority review by the FDA in September 2007.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES